RABYD-VAX is a collaborative research project funded under the EU’s Framework Programme for Research and Innovation (Horizon 2020), coordinated by the University of Leuven (KU Leuven) and conducted by five European research institutes. Our research focuses on the development of a novel dual rabies – yellow fever vaccine.
RABYD-VAX combines the expertise of five European research institutes to develop and validate a vaccine that protects against both rabies and yellow fever/Japanese encephalitis virus and which could ultimately be given as a prophylactic childhood vaccine incorporated in the standard childhood vaccination schedule of endemic regions. This side-by-side with domestic and wildlife animal vaccination programmes… Continue reading About RABYD-VAX
WIV press corner: The Belgian Institute of Public Health (WIV-ISP) participates in the development of a new vaccine against rabies and yellow fever. KU leuven news site: KU Leuven to lead development of dual vaccine against yellow fever and rabies. Twitter University of Leuven @LeuvenU
RABYD-VAX officially started its activities with the kick-off meeting held in Leuven, Belgium on the 11th of January 2017. This meeting was hosted by the University of Leuven (KU Leuven) at the Rega Institute for Medical Research, which is also the coordinator of this collaborative research project. RABYD-VAX was created in response to a Horizon… Continue reading RABYD-VAX Kick-off Meeting
Information about the global campaign to get rid of rabies